It has been shown to be related to biphasic morphology.[23,27] Comprehensive analysis provides a favorable basis for PD-L1 as an immunotherapy or targeted therapy for TFEB-associated renal cell carcinoma, but further studies are necessary. Here, CD274 is linked to renal cell carcinoma.